Efficacy and safety of atomoxetine in childhood Attention-Deficit/Hyperactivity Disorder with comorbid Oppositional Defiant Disorder
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: To compare the safety and efficacy of atomoxetine, a selective inhibitor of the norepinephrine transporter, versus placebo in Attention-Deficit/Hyperactivity Disorder (ADHD) patients with comorbid Oppositional Defiant Disorder (ODD). Methods: A subset analysis of 98 children from two identical, multi-site, double-blind, randomized, placebo-controlled trials involving 9 weeks of treatment with atomoxetine or placebo was conducted. Patients met DSM-IV ADHD criteria. ODD was diagnosed with the Diagnostic Interview for Children and Adolescents-IV (DICA-IV; Reich, Welner, & Herjanic, 1997). ADHD severity was assessed with the ADHD Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHD-RS-IV-Parent:Inv; DuPaul, Power, Anastopoulos, & Reid, 1998); the short version of the Conners’ Parent Rating Scales-Revised (CPRS-R:S; Conners, 2000); and the Clinical Global Impressions of ADHD Severity (CGI-ADHD-S; Guy, 1976). Clinical response was defined as a ≥ 25% reduction in ADHD-RS-IV-Parent:Inv total score. Results: ADHD-RS-IV-Parent:Inv, CGI-ADHD-S, and three CPRS-R:S subscale scores improved markedly with atomoxetine treatment. However, a decrease in the CPRS-R:S Oppositional subscore for atomoxetine-treated patients was not significantly greater than scores for placebo-treated patients. Clinical response rates were 65.4% in the atomoxetine group, and 36.4% in the placebo group ( p = .007). Conclusion: Atomoxetine was effective for the treatment of ADHD in patients with comorbid ODD. It did not significantly reduce the severity of ODD symptoms, and was well tolerated by the patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Goldman, L. S. (1998) · JAMA · doi:10.1001/jama.279.14.1100 · Cited by 1,082 · cited 1×
“ODD is a common comorbid condition of ADHD, occurring in up to 40% of childhood cases (Goldman et al., 1998).”
BackgroundCommittee on Quality Improvement, S. O. A.-D. D. (2000) · Pediatrics · doi:10.1542/peds.105.5.1158 · Cited by 1,076 · cited 1×
“The recently published American Academy of Pediatrics ADHD treatment guidelines suggest a prevalence rate of 8% to 10% (American Academy of Pediatrics, 2000).”
BackgroundMichelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Self-citationMichelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 1×
“Nevertheless, such studies have been conducted in noncomorbid patients with ADHD using both the Conners’ Teacher Rating Scale (Michelson et al., 2002) and the ADHD-RS-IV-Teacher:Inv (Kratochvil, 2003), and these corroborate the findings in the present study.”
ResultSelf-citationKlein, R. G. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830240023003 · Cited by 349 · cited 1×
“In some patients, ODD may progress to Conduct Disorder, which has been well described and distinguished from ADHD (Klein et al., 1997), and which may ultimately manifest in young adults as Antisocial Personality Disorder.”
BackgroundSpencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333 · cited 1×
“Early in the development of atomoxetine we conducted two identical, randomized, double-blind trials that assessed the safety and efficacy of atomoxetine compared with placebo in pediatric patients with ADHD (Spencer et al., 2002).”
MethodSelf-citationImpact of Comorbid Oppositional or Conduct Problems on Attention-Deficit Hyperactivity Disorder
KUHNE, M., SCHACHAR, R., & TANNOCK, R. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199712000-00020 · Cited by 209 · cited 1×
“These behaviors cause significant impairment in family and social functioning (Kuhne et al., 1997).”
BackgroundWeiss, M., Tannock, R., Kratochvil, C., Dunn, D., Velez-Borras, J., Thomason, C., Tamura, R., Kelsey, D., Stevens, L., & Allen, A. J. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000163280.47221.c9 · Cited by 147
Cited by
Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., Buitelaar, J., Danckaerts, M., Döpfner, M., Faraone, S. V., Rothenberger, A., et al. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0549-0 · Cited by 375
Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial
ARNOLD, L. E., AMAN, M. G., COOK, A. M., WITWER, A. N., HALL, K. L., THOMPSON, S., & RAMADAN, Y. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000231976.28719.2a · Cited by 260
Connor, D. F., Steeber, J., & McBurnett, K. (2010) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e3181e121bd · Cited by 218
Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0840-x · Cited by 185
“To investigate the efficacy of atomoxetine compared to placebo in reducing ADHD and ODD symptoms, we performed another set of meta-analyses (Table 3) on atomoxetine RCTs that included only comorbid ADHD+ODD subjects (Table 1).”
BackgroundInfluentialM. Robertson*, M. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0505-z · Cited by 143
“Atomoxetine has in both open studies (Buitelaar et al. 2004; Adler et al.2005; Escobar et al.2005) and DBTs (Michelson et al. 2001; Kaplan et al. 2004; Kelsey et al. 2004), and reviews (Banaschewski et al.2004;Himpel et al.2005) been shown to be effective in ADHD.”
Metadata
- Authors
- Kaplan, S., Heiligenstein, J., West, S., Busner, J., Harder, D., Dittmann, R., Casat, C., & Wernicke, J. F.
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2004-10
- Volume
- 8
- Issue
- 2
- Pages
- 45-52
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- OpenAlex
- W2117095140
- Cited by
- 66
- References
- 10
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of atomoxetine in childhood Attention-Deficit/Hyperactivity Disorder with comorbid Oppositional Defiant Disorder. https://app.cochat.ai/papers/10.1177/108705470400800202
- The paper
- Kaplan, S., Heiligenstein, J., West, S., Busner, J., Harder, D., Dittmann, R., Casat, C., & Wernicke, J. F. (2004). Efficacy and safety of atomoxetine in childhood Attention-Deficit/Hyperactivity Disorder with comorbid Oppositional Defiant Disorder. Journal of Attention Disorders. https://doi.org/10.1177/108705470400800202
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.